



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Nadunolimab

|                  |   |
|------------------|---|
| <b>Cat. No.:</b> | HY-P99235   |
| <b>Target:</b>   | Interleukin Related   |
| <b>Pathway:</b>  | Immunology/Inflammation   |
| <b>Storage:</b>  | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

|                                     |  |  |
|-------------------------------------|--|--|
| <b>Description</b>                  | Nadunolimab is a human monoclonal IgG1 antibody targeting IL1RAP. Nadunolimab blocks IL-1 $\alpha$ and IL-1 $\beta$ signaling and triggering antibody-dependent cellular cytotoxicity. Nadunolimab can be used in research of cancer <sup>[1]</sup> .  |  |
| <b>IC<sub>50</sub> &amp; Target</b> | IL-1 $\alpha$  | IL-1 $\beta$   |
| <b>In Vitro</b>                     | Nadunolimab (20 $\mu$ g/mL; 30 min and 1 h; A549 cells and BxPC3 cells) reduces IL-1 $\alpha$ -induced release of pro-inflammatory cytokines and chemokines, including IL-1 $\beta$ , IL-6, TNF- $\alpha$ and MIP-1 $\alpha$ , and CXCL1 <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |  |
| <b>In Vivo</b>                      | Nadunolimab (10 mg/kg; i.p.; twice on day 1 and thereafter twice weekly; nude BALB/c mice with LU2503 or MC38 tumors) improves the anti-tumor efficacy of chemotherapy and blocks both murine IL-1 $\alpha$ and IL-1 $\beta$ signaling <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.   |  |
|                                     | <b>Animal Model:</b>   | Nude BALB/c mice with LU2503 or MC38 tumors <sup>[1]</sup>   |
|                                     | <b>Dosage:</b>   | 10 mg/kg   |
|                                     | <b>Administration:</b>   | Intraperitoneal injection; twice on day 1 and thereafter twice weekly  |
|                                     | <b>Result:</b>   | Reduced tumor volume in combination with <a href="#">Cisplatin</a> (HY-17394) and <a href="#">Gemcitabine</a> (HY-17026).<br>Blocked both murine IL-1 $\alpha$ and IL-1 $\beta$ signaling. |

### REFERENCES

[1]. Rydberg Millrud C, et, al. Blockade of IL-1 $\alpha$  and IL-1 $\beta$  signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA